AngioDynamics (NASDAQ:ANGO) Releases FY25 Earnings Guidance

Posted by Tammy Falkenburg on Jan 8th, 2025

AngioDynamics (NASDAQ:ANGO – Get Free Report) updated its FY25 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of ($0.38)-($0.34) for the period, compared to the consensus estimate of ($0.40). The company issued revenue guidance of $282-288 million, compared to the consensus revenue estimate of $283.86 million. AngioDynamics also updated its FY 2025 guidance to -0.380–0.340 EPS.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ANGO. Canaccord Genuity Group dropped their price target on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, October 4th. HC Wainwright restated a “buy” rating and set a $14.00 price objective on shares of AngioDynamics in a report on Tuesday, December 10th.

Get Our Latest Stock Analysis on AngioDynamics

AngioDynamics Stock Performance

NASDAQ ANGO opened at $9.40 on Wednesday. AngioDynamics has a one year low of $5.26 and a one year high of $9.63. The company’s 50 day moving average price is $7.82 and its 200 day moving average price is $7.27. The firm has a market capitalization of $381.96 million, a price-to-earnings ratio of -1.54 and a beta of 0.59.

AngioDynamics (NASDAQ:ANGO – Get Free Report) last announced its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The firm had revenue of $72.90 million during the quarter, compared to analysts’ expectations of $70.93 million. AngioDynamics’s revenue for the quarter was down .1% on a year-over-year basis. Sell-side analysts forecast that AngioDynamics will post -0.41 EPS for the current fiscal year.

AngioDynamics Company Profile

(Get Free Report)

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.